BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Viral cancer immunotherapy company Oncorus Inc. hired John McCabe as CFO. He was CFO of Flex Pharma Inc....
BioCentury | Dec 7, 2018
Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

...Neurodegeneration company Asceneuron S.A. (Lausanne, Switzerland) hired Thomas Wessel as CMO. He was CMO at Flex Pharma Inc....
BioCentury | Jun 15, 2018
Clinical News

Flex downsizing on troubles with sole clinical program

...loss of $8.3 million. In 2017, the company reported an operating loss of $34.7 million. Flex Pharma Inc....
...amyotrophic lateral sclerosis (ALS); treat Charcot-Marie-Tooth (CMT) disease Endpoint: NA Status: Development discontinued Milestone: NA Jennie Walters FLX-787 Flex Pharma Inc. Transient...
BioCentury | Jun 13, 2018
Clinical News

Flex downsizing on troubles with sole clinical program

...loss of $8.3 million. In 2017, the company reported an operating loss of $34.7 million. Jennie Walters FLX-787 Flex Pharma Inc. Transient...
BioCentury | Apr 20, 2018
Clinical News

Flex reports Phase II data for FLX-787 in MS patients

...dual transient receptor potential vanilloid 1 (TRPV1; VR1) and transient receptor potential A1 (TRPA1) agonist. Flex Pharma Inc....
...Endpoint: Frequency of cramps, spasms and spasticity and safety Status: Phase II data Milestone: NA Allison Johnson FLX-787 Flex Pharma Inc. Transient...
BioCentury | Sep 22, 2017
Financial News

Lightstone closes $250M fund

...investments including rare disease and lipid disorders company Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), neurological diseases company Flex Pharma Inc....
...May 5, 2014 & Feb. 22, 2016 ). Lightstone Ventures, Menlo Park, Calif. Alicia Parker Catabasis Pharmaceuticals Inc. Flex Pharma Inc. Ra...
BioCentury | Sep 20, 2017
Financial News

Lightstone closes $250M fund

...investments including rare disease and lipid disorders company Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), neurological diseases company Flex Pharma Inc....
BioCentury | Aug 1, 2017
Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

...the company by Jan. 31, 2018. The company is seeking a replacement. Neurological disease play Flex Pharma Inc....
BioCentury | Jun 9, 2017
Company News

Management tracks

...Neurological diseases play Flex Pharma Inc. (NASDAQ:FLKS) said Christoph Westphal will step down as CEO, effective July 3...
BioCentury | Oct 24, 2016
Clinical News

FLX-787: Clinical trial data

...half, Flex plans to start a Phase II trial of FLX-787 in nocturnal leg cramps. Flex Pharma Inc....
Items per page:
1 - 10 of 32
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Viral cancer immunotherapy company Oncorus Inc. hired John McCabe as CFO. He was CFO of Flex Pharma Inc....
BioCentury | Dec 7, 2018
Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

...Neurodegeneration company Asceneuron S.A. (Lausanne, Switzerland) hired Thomas Wessel as CMO. He was CMO at Flex Pharma Inc....
BioCentury | Jun 15, 2018
Clinical News

Flex downsizing on troubles with sole clinical program

...loss of $8.3 million. In 2017, the company reported an operating loss of $34.7 million. Flex Pharma Inc....
...amyotrophic lateral sclerosis (ALS); treat Charcot-Marie-Tooth (CMT) disease Endpoint: NA Status: Development discontinued Milestone: NA Jennie Walters FLX-787 Flex Pharma Inc. Transient...
BioCentury | Jun 13, 2018
Clinical News

Flex downsizing on troubles with sole clinical program

...loss of $8.3 million. In 2017, the company reported an operating loss of $34.7 million. Jennie Walters FLX-787 Flex Pharma Inc. Transient...
BioCentury | Apr 20, 2018
Clinical News

Flex reports Phase II data for FLX-787 in MS patients

...dual transient receptor potential vanilloid 1 (TRPV1; VR1) and transient receptor potential A1 (TRPA1) agonist. Flex Pharma Inc....
...Endpoint: Frequency of cramps, spasms and spasticity and safety Status: Phase II data Milestone: NA Allison Johnson FLX-787 Flex Pharma Inc. Transient...
BioCentury | Sep 22, 2017
Financial News

Lightstone closes $250M fund

...investments including rare disease and lipid disorders company Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), neurological diseases company Flex Pharma Inc....
...May 5, 2014 & Feb. 22, 2016 ). Lightstone Ventures, Menlo Park, Calif. Alicia Parker Catabasis Pharmaceuticals Inc. Flex Pharma Inc. Ra...
BioCentury | Sep 20, 2017
Financial News

Lightstone closes $250M fund

...investments including rare disease and lipid disorders company Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), neurological diseases company Flex Pharma Inc....
BioCentury | Aug 1, 2017
Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

...the company by Jan. 31, 2018. The company is seeking a replacement. Neurological disease play Flex Pharma Inc....
BioCentury | Jun 9, 2017
Company News

Management tracks

...Neurological diseases play Flex Pharma Inc. (NASDAQ:FLKS) said Christoph Westphal will step down as CEO, effective July 3...
BioCentury | Oct 24, 2016
Clinical News

FLX-787: Clinical trial data

...half, Flex plans to start a Phase II trial of FLX-787 in nocturnal leg cramps. Flex Pharma Inc....
Items per page:
1 - 10 of 32